2020-09-02

Umecrine Cognition to present clinical Phase 2a results at AASLD International Liver Meeting

 

2020-05-08

Umecrine Cognition announces positive additional endpoint data from a phase 2a study with golexanolone in hepatic encephalopathy

 

2020-04-03

Umecrine Cognition announces top-line results from its phase 2a study with golexanolone in hepatic encephalopathy

 

2019-12-20

 Umecrine Cognition announces a Notice of Allowance from USPTO for a patent protecting a pharmaceutical formulation of its proprietary lead compound golexanolone

 

2019-12-13

Umecrine Cognition announces completion of enrollment in clinical Phase 2a study with golexanolone in patients with liver cirrhosis and hepatic encephalopathy

​

2019-02-18

Umecrine Cognition announces first patient included in part D in clinical Phase 2a study with GR3027 in patients with liver cirrhosis and hepatic encephalopathy

​

2019-01-29

Umecrine Cognition announces results from a Phase 2a study of GR3027 in patients with idiopathic hypersomnia

​

2018-12-12

Umecrine Cognition granted a European patent protecting its lead candidate drug GR3027

​

2018-12-03

Umecrine Cognition appoints Dr. Eva Arlander as Chief Development Officer

 

2018-03-02

Umecrine Cognition announces on-line publication of Clinical trial results perteining to GR3027 safety, pharmacokinetics and CNS target engagement

​

2017-11-20

Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder

 

2017-10-04

Umecrine Cognition raises SEK 20 million to treat unmet needs in sleep disorder

 

2017-09-13

Umecrine Cognition announces positive data from its Phase 1b study of GR3027 - a potential new treatment of hepatic encephalopathy

 

2017-09-05

Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors

 

2017-04-21

Umecrine Cognition to present at the EASL International Liver Congress 2017

​

2017-03-17

Umecrine Cognition announces first patient included in Clinical Phase 1b/2a study with GR3027, a novel drug candidate for Hepatic Encephalopathy

 

2016-11-22

Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy

 

2016-11-03

Positive Phase 1 top line data with GR3027 demonstrate safety, tolerability, and CNS target engagement

​

2016-07-05

Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors.

2016-03-10

Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for Hepatic Encephalopathy - Phase I clinical trial initiated.

2015-12-09

Umecrine Cognition announces grant of a US patent protecting its lead candidate drug GR3027.

2015-08-19

GR3027 normalizes the neurolological symptoms in two preclinical models of Hepatic Encephalopathy.

2013-10-23

Umecrine Cognition signs partnering agreement with CleveXel Pharma.

2012-02-01
Magnus Doverskog appointed as new CEO for Umecrine Cognition.